Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Deltex Medical Group Plc LSE:DEMG London Ordinary Share GB0059337583 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 1.325 124,423 08:00:00
Bid Price Offer Price High Price Low Price Open Price
1.25 1.40 1.325 1.325 1.325
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 4.26 -0.21 -0.03 7
Last Trade Time Trade Type Trade Size Trade Price Currency
12:02:45 O 76,149 1.31 GBX

Deltex Medical (DEMG) Latest News

More Deltex Medical News
Deltex Medical Investors    Deltex Medical Takeover Rumours

Deltex Medical (DEMG) Discussions and Chat

Deltex Medical Forums and Chat

Date Time Title Posts
28/11/202005:27Deltex Medical - a British success story!11,198
21/9/202008:16Deltex Medical-Optimal Growth Stock10,013
05/6/202013:27Deltex Medical - winner or doomed to fail? 410
22/3/201209:04Deltex Medical - Past, Present and Future-
07/12/201111:57Deltex Medical - More key endorsements-

Add a New Thread

Deltex Medical (DEMG) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Deltex Medical trades in real-time

Deltex Medical (DEMG) Top Chat Posts

DateSubject
28/11/2020
08:20
Deltex Medical Daily Update: Deltex Medical Group Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker DEMG. The last closing price for Deltex Medical was 1.33p.
Deltex Medical Group Plc has a 4 week average price of 1.18p and a 12 week average price of 1.18p.
The 1 year high share price is 2.75p while the 1 year low share price is currently 0.90p.
There are currently 524,464,064 shares in issue and the average daily traded volume is 336,292 shares. The market capitalisation of Deltex Medical Group Plc is £6,949,148.85.
03/11/2020
12:42
nobbygnome: >> mrc You obviously haven't done your research properly if you are not aware of this major difference. DEMG took the approach of building the evidence base which is relatively costly and time consuming. Sadly that has meant that they have always had limited resources for proper marketing and the rest of the story is history. However, all the other players in the industry are fully aware of the massive advantage ODM has in surgery over the other technologies which is why a proper valuation will be achieved if/when DEMG is bought out. FWIW I think Edwards are the most likely acquirers as I know DEMG have had informally talks with them for years. All just IMHO...
02/11/2020
07:32
nobbygnome: Yes should be good news for DEMG share price as it will show the true value of a business like this!
27/10/2020
13:45
mrc2u: Anyway, I have held off on LID's interims compared to DEMG's but LID had sales of 6.2m and DEMG of 1.2m. That is five times higherAnd DEMG only needed to have sold 7,000 less to have rounded to £1.1m which would have made LID over 5.5 times higherI get there are different exposures to surgery between the two but DEMG has a great ICU product especially in ventilated patientsSo, why were LID able to generate £2,698k of monitor sales to the NHS in six months, up 12x on previous fist half? And why were DEMG only able to generate monitor sales of £16k, down from £19k?There was a windfall to be had and LID grabbed it. DEMG totally missed it. DEMG monitor sales in the UK were less than 150th of LIDWhy?Because they have spent over a decade failing to develop a new monitor. Why? What are they doing about it? Who is to blame? Who is sorting it out?But maybe also because they don't know how to sell?What is needed is:New chairNew, smaller, boardNew brokersNew monitorNew marketing storyNew business modelLID has done all the above, DEMG none of it and now DEMG have been shown to have been swimming naked for yearsMrC
24/8/2020
07:11
mrc2u: Well done to LID for a very strong first half. They have taken full advantage of the CoVid gift horse and GROWN their core product sales by 83% to 6.1mDEMG, on the other hand, somehow managed to totally miss the gift horse and saw (yet another) sharp decline in sales to 1.2mFrom parity with LID in 2017 to selling less than one fifth two and a half years later is a truly dreadful performance by DEMGHeads must roll and they must roll now. Absolutely shocking and heaven only knows what this will do to the relative share pricesTerrible start to the week. Although glad I bought a few LID at half the current priceMrC
11/8/2020
08:53
gbenson1: Hi mrC2u, whilst I can't agree that DEMG are showing signs of a sell, I do agree with some of your observations! DEMG is grossly undervalued at the moment and I expect a 2.30p Sp would be fair value. The company need a bright professional CEO with the highest Medical background and not someone who has come through the ranks and was a cheap alternative. I believe another way to realise the true value of the technology is for a larger company to take over DEMG and give it the backing/promotion it deserves to realise it's true potential. A new driven advisor would in part get DEMGs proven and tested equipment to a wider audience. With the recent large placing @1p perhaps a consolidation of the Sp to say 1 for 5 or 1 for 10 may help in the markets. A bid premium of 7-8p per share would not be excessive.
31/7/2020
15:31
mrc2u: >>gbensonAfraid I will be keeping my attention over here as I have as many millions of DEMG as I do hundreds of thousands of LIDHave done my homework on the two core technologies and think DEMG's works and LID's doesn't. Therefore keen to understand how DEMG have fallen so far behind in two years that they will not sell as much in the whole year as LID did in the first quarter I get that LID have a monitor to sell to hospitals and DEMG have one to sell to museums but that is within DEMG's control, surely? They have been working on a new one for at least a decade and I, and many others, have put in new cash at least twice to fund one. Where on earth is it???The conclusion must be that LID are doing something right and, lo and behold, it turns out they have actually being doing the things I have been droning on as needing doing by DEMGOnce DEMG have done them, it will be a far better investment IMHO but getting desperate to see urgency and not more facile upbeat platitudes in every updateOff to sit in the paddling poolMrC
19/7/2020
21:18
buywell3: ==== buywell takes a look at one of DEMG major shareholders ===== ===== Michael Stubbs first announced on Feb 5th 2019 that he had acquired ===== 15,950,000 shares in DEMG --- 3.18% Though the date , see note --- vi The date on which threshold is crossed or reached should be the date on which the acquisition or disposal took place or the other reason triggered the notification obligation. For passive crossings, the date when the corporate event took effect. This date was months earlier on ---- 3rd December 2018 buywell has NEVER seen such a long notification RNS delay The above chart starts 17th Sept 2018 and ends 3rd Dec 2018 ( Date threshold ie 3% was crossed ) The place of completion or address ------ Place of completion ---- Gloucester buywell thinks it logical that Michael Stubbs from Gloucester bought just under 3% earlier around Sept when the price bombed eg around 1.3p the current share price. Remember when looking at volumes on the chart a volume of 15M = half sells and half buys ie 7.5M of each dyor
01/5/2020
17:06
schloo: Vega On the remote chance that you really want your question answered DEMG built a robust evidence base of improved outcome and reduced costs after surgery. NICE reviewed the evidence and agreed, giving CardioQ-ODM a whole-hearted & wide ranging recommendation. This led to the NHS deciding to roll out ODM fully at pace and scale across the NHS: this is still the only time that the NHS has decided to roll out a medtech product nationally on the basis of evidence LID has tried to build an evidence base in surgery but has consistently failed. This does not mean its tech doesn't work in surgery, just that it is nothing like as effective as DEMG's So far so good: DEMG was flying in surgery, LID struggling The NHS, after intense lobbying from LID, Edwards & others with inferior technologies, moved from implementing CardioQ-ODM, which had been reviewed by NICE, to ODM in general and then to ODM or similar technologies and then to any technology making marketing claims. Other than CardioQ-ODM they did not, and, disgracefully, still have not actually looked at the evidence nor allowed NICE to do so This gave LID a huge leg up. The LID product, or at least the LidcoRapid, is much easier to use than ODM so anybody who believed they were the same would be justified in choosing the easy one rather than the one requiring more effort, skill and interpretation. Much easier for LID or Edwards sales reps to sell their kit as being as good as ODM when the NHS was telling them, wrongly, that it was the same thing Then the NHS pulled its national roll-out programme anyway for idiotic bureaucratic reasons, causing a backlash against DEMG from doctors who had not liked being told to change their practice and blamed DEMG for a cynical exploitation of its (objective) evidence base. Nobody else was blamed because they hadn't exploited evidence they didn't have There are other layers to the shambles but, basically, LID got lucky while DEMG got shafted HOWEVER that is in the past. DEMG now sells the same entry level tech as LID but also offers a good non-invasive impedance tech as well as ODM off the same platform. Once they have a shiny new box (soon) DEMG should start to regain share quite rapidly More importantly, it can only be a matter of time before someone, somewhere looks objectively at the LID evidence during surgery. They have done at least 10 studies and have not got one single positive result. DEMG have done over 20 and have over 20 positive results Long term it really does matter that ODM is superior - avoidable complications after surgery kill in CoVid type numbers every year so this will one day get the attention it merits and LID's bluff will be well & truly called and whoever owns DEMG will make monstrous returns That said, I think LID has a good monitoring technology, some well designed products and is well run these days by a good team. I own some shares, have doubled my money recently and think there is still plenty of upside. DEMG could and should learn from them. However, I don't think they are a great takeover candidate because their technology is not that well differentiated so they are selling revenues and profits more than DEMG who are selling unique and proven tech for which there is a clear and massive global need. I.e. any of Edwards, Baxter, Medtronic, J&J and so on could do far far more with DEMG than LID. I own a lot more of DEMG than I do of LID Hope that helps Schloo
30/4/2020
19:18
nobbygnome: Cheetah a private company who have an inferior technolgy were taken over for the equivalent DEMG price of 10p. A big acquirer like Edwards would value the technology on a multiple of turnover because they know with a bit of marketing spend they could massively increase that turnover. DEMG have spent years building an evidence base which shows their technology works the best in the field. That has a big value to a company like Edwards. LID most definitely do not hav ethat evidence based and their market cap is well above DEMG at present. Oh and their technology is not proven to work in surgery.... DEMG is still cheap at this level. I was buying this afternoon when the price pulled back!
30/4/2020
07:55
schloo: DEMG has ALL the best and highest quality evidence re the massive surgery market and no other company can come close. The evidence is clear that patients managed with ODM avoid more complications than those on whom it is not used. The cost of ODM is paid back many times over in the hospital episode when it is used as well as in QALYs After 30 years DEMG is now profitable and generating cash DEMG's market cap has just recovered to around £12.5m. A direct competitor which was gushing out cash and treating the same number of patients at similar margins was recently bought for £170m, more than 13 times the DEMG market cap. DEMG's platform approach offers the same bioimpedance technology as well as the gold standard ODM and the entry level PPWA Cheetah aside, big medtechs mostly only buy small medtechs once they are cash positive. DEMG is CoVid is hammering home in the most brutal way possible that getting haemodynamics right at a time of crisis is a matter of life and death and DEMG has the only technology that actually and directly measures central blood flows Brilliant technology at very low prices with a massive global crisis setting it up for a surge in sales as well as a takeover Suggest you sit back, shut up and enjoy the ride PS you really are very very thick, aren't you? If all the costs stay flat, to achieve a standstill in profits, you need, er, flat sales
Deltex Medical share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
DEMG
Deltex Med..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201129 06:25:08